The study also reported a 42% lower risk of psychiatric hospitalizations and work absences during periods when patients were ...

GLP receptor agonists tied to lower substance use disorder risk in veterans, reducing emergency visits, hospitalizations, and overdose incidents.

Researchers have found that adults who stop taking GLP-1 receptor agonist drugs such as semaglutide and tirzepatide face a measurable increase in heart attack, stroke, and death risk within months of ...

Taking GLP-1 RAs is associated with fewer hospitalizations overall and less need for medications used to stop and prevent ...

All-cause mortality significantly lower with GLP-1 RA use, with consistent benefit across major cancer types, most GLP-1 RA types.

The use of GLP-1 RAs for weight loss proved to be similarly effective across different age groups, races, and starting weights in adults.

The researchers found that GLP-1 RA use was associated with significantly lower odds of vertebral compression fractures compared with nonuse. (HealthDay News) — Glucagon-like peptide 1 receptor ...

The use of glucagon-like peptide-1 (GLP-1) receptor agonists is associated with reduced risks for developing substance use disorders (SUDs).

Initiation of GLP-1 receptor agonists was linked to fewer asthma exacerbations across overweight, obese, and morbidly obese patient cohorts.

Glucagon-like peptide-1 receptor agonist therapy with liraglutide or semaglutide is not associated with an increased risk for thyroid cancer among patients with type 2 diabetes or obesity, according ...

GoodRx reports that GLP-1 medications will expand in use and accessibility, with new oral options and evolving insurance coverage trends.

Results showed that use of GLP-1 receptor agonists did not increase short-term medical or surgical complications among ...